Rac1/Pak1/p38/MMP-2 axis regulates angiogenesis in ovarian cancer

Clinical Cancer Research

Volumn 21, Issue 9, 2015, Pages 2127-2137

  Gonzalez Villasana, Vianey ^a   Fuentes Mattei, Enrique ^a   Ivan, Cristina ^a   Dalton, Heather J ^a   Rodriguez Aguayo, Cristian ^a   Fernandez De Thomas, Ricardo J ^a   Aslan, Burcu ^a   Monroig, Paloma Del C ^a,b   Velazquez Torres, Guermarie ^a   Previs, Rebecca A ^a   Pradeep, Sunila ^a   Kahraman, Nermin ^a   Wang, Huamin ^a   Kanlikilicer, Pinar ^a   Ozpolat, Bulent ^a   Calin, George ^a   Sood, Anil K ^a   Lopez Berestein, Gabriel ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF PUERTO RICO SCHOOL OF MEDICINE   (Puerto Rico)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BONE MORPHOGENETIC PROTEIN 9; CD31 ANTIGEN; ENDOGLIN; ENDOTHELIN 1; EPIDERMAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FOLLISTATIN; GELATINASE A; GELATINASE B; GRANULOCYTE COLONY STIMULATING FACTOR; HEPARIN BINDING EPIDERMAL GROWTH FACTOR; INTERLEUKIN 8; INTERSTITIAL COLLAGENASE; KI 67 ANTIGEN; LEPTIN; MATRILYSIN; MITOGEN ACTIVATED PROTEIN KINASE P38; P21 ACTIVATED KINASE 1; PACLITAXEL; PLACENTAL GROWTH FACTOR; RAC1 PROTEIN; SCATTER FACTOR; STROMELYSIN 2; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN D; ZOLEDRONIC ACID; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE; P21 ACTIVATED KINASE; PAK1 PROTEIN, HUMAN; RAC1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; DRUG EFFECTS; DRUG SCREENING; GENETIC TRANSFECTION; HIGH THROUGHPUT SCREENING; IMMUNOHISTOCHEMISTRY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; OVARY TUMOR; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; WESTERN BLOTTING;

ALBUMINS; ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DIPHOSPHONATES; FEMALE; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; IMIDAZOLES; IMMUNOHISTOCHEMISTRY; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; OVARIAN NEOPLASMS; P21-ACTIVATED KINASES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PACLITAXEL; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84930651943     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2279     Document Type: Article

References (50)

1. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer 2009;9:167-81.
2. Kim A, Ueda Y, Naka T, Enomoto T. Therapeutic strategies in epithelial ovarian cancer. J Exp Clin Cancer Res 2012;31:14.
3. Gomez-Raposo C, Mendiola M, Barriuso J, Casado E, Hardisson D, Redondo A. Angiogenesis and ovarian cancer. Clin Transl Oncol 2009;11: 564-71.
4. Spannuth WA, Sood AK, Coleman RL. Angiogenesis as a strategic target for ovarian cancer therapy. Nat Clin Pract Oncol 2008;5:194-204.
5. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011;473:298-307.
6. Raja FA, Hook JM, Ledermann JA. Biomarkers in the development of anti-angiogenic therapies for ovarian cancer. Cancer Treat Rev 2012;38: 662-72.
7. Stresing V, Fournier PG, Bellahcene A, Benzaid I, MonkkonenH, Colombel M, et al. Nitrogen-containing bisphosphonates can inhibit angiogenesis in vivo without the involvement of farnesyl pyrophosphate synthase. Bone 2011;48:259-66.
8. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002;302:1055-61.
9. Misso G, Porru M, Stoppacciaro A, Castellano M, De Cicco F, Leonetti C, et al. Evaluation of the in vitro and in vivo antiangiogenic effects of denosumab and zoledronic acid. Cancer Biol Ther 2012;13:1491-500.
10. Knight LA, Kurbacher CM, Glaysher S, Fernando A, Reichelt R,Dexel S, et al. Activity of mevalonate pathway inhibitors against breast and ovarian cancers in the ATP-based tumour chemosensitivity assay. BMC Cancer 2009;9:38.
11. Clezardin P. Insights into the antitumor effects of bisphosphonates from preclinical models and potential clinical implications. Int Bone Miner Soc 2009;6:210-7.
12. Bid HK, Roberts RD, Manchanda PK, Houghton PJ. RAC1: an emerging therapeutic option for targeting cancer angiogenesis and metastasis. Mol Cancer Ther 2013;12:1925-34.
13. Tan W, Palmby TR, Gavard J, Amornphimoltham P, Zheng Y, Gutkind JS. An essential role for Rac1 in endothelial cell function and vascular development. FASEB J 2008;22:1829-38.
14. Moreno-Smith M, Halder JB, Meltzer PS, Gonda TA, Mangala LS, Rupaimoole R, et al. ATP11B mediates platinum resistance in ovarian cancer. J Clin Invest 2013;123:2119-30.
15. Gonzalez-Villasana V, Nieves-Alicea R, McMurtry V, Gutierrez-Puente Y, TariAM. Programmed cell death 4 inhibits leptin-induced breast cancer cell invasion. Oncol Rep 2012;27:861-6.
16. Pecot CV, Rupaimoole R, Yang D, Akbani R, Ivan C, Lu CH, et al. Tumour angiogenesis regulation by the miR-200 family. Nat Commun 2013;4: 2427.
17. Freireich EJ, Gehan EA, Rall DP, Schmidt LH, Skipper HE. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. Cancer Chemother Rep 1966;50:219-44.
18. Administration FaD. Guidance for Industry Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers. [cited July 6, 2005]. Available from http://www.fda.gov/downloads/Drugs/Guidances/UCM078932.pdf.
19. Gonzalez-Villasana V, Rodriguez-Aguayo C, Arumugam T, Cruz-Monserrate Z, Fuentes-Mattei E,DengD, et al. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound Paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther 2014;13:2583-94.
20. Lu C, Kamat AA, Lin YG, Merritt WM, Landen CN, Kim TJ, et al. Dual targeting of endothelial cells and pericytes in antivascular therapy for ovarian carcinoma. Clin Cancer Res 2007;13:4209-17.
21. del Barco Barrantes I, Nebreda AR. Roles of p38 MAPKs in invasion and metastasis. Biochem Soc Trans 2012;40:79-84.
22. Liu XY, Zhang L, Wu J, Zhou L, Ren YJ, Yang WQ, et al. Inhibition of elongation factor-2 kinase augments the antitumor activity of Temozolomide against glioma. PLoS One 2013;8:e81345.
23. Wu G, Luo J, Rana JS, Laham R, Sellke FW, Li J. Involvement of COX-2 in VEGF-induced angiogenesis via P38 and JNK pathways in vascular endothelial cells. Cardiovasc Res 2006;69:512-9.
24. Khan AA, Dace DS, Ryazanov AG, Kelly J, Apte RS. Resveratrol regulates pathologic angiogenesis by a eukaryotic elongation factor-2 kinase-regulated pathway. Am J Pathol 2010;177:481-92.
25. Zhang S, Han J, Sells MA, Chernoff J, Knaus UG, Ulevitch RJ, et al. Rho family GTPases regulate p38 mitogen-activated protein kinase through the downstream mediator Pak1. J Biol Chem 1995;270:23934-6.
26. Kumar R, Gururaj AE, Barnes CJ. p21-activated kinases in cancer. Nat Rev Cancer 2006;6:459-71.
27. Zhong J, Gencay MM, Bubendorf L, Burgess JK, Parson H, Robinson BW, et al. ERK1/2 and p38 MAP kinase control MMP-2, MT1-MMP, and TIMP action and affect cell migration: a comparison between mesothelioma and mesothelial cells. J Cell Physiol 2006;207:540-52.
28. Lin ML, Lu YC, Chung JG, Wang SG, Lin HT, Kang SE, et al. Downregulation of MMP-2 through the p38 MAPK-NF-kappaB-dependent pathway by aloe-emodin leads to inhibition of nasopharyngeal carcinoma cell invasion. Mol Carcinog 2010;49:783-97.
29. Michailidou M, Brown HK, Lefley DV, Evans A, Cross SS, Coleman RE, et al. Microvascular endothelial cell responses in vitro and in vivo: modulation by zoledronic acid and paclitaxel? J Vasc Res 2010;47:481-93.
30. Holen I, Coleman RE. Anti-tumour activity of bisphosphonates in preclinical models of breast cancer. Breast Cancer Res 2010;12:214.
31. Wakchoure S, Merrell MA, Aldrich W, Millender-Swain T, Harris KW, Triozzi P, et al. Bisphosphonates inhibit the growth of mesothelioma cells in vitro and in vivo. Clin Cancer Res 2006;12:2862-8.
32. Zarubin T, Han J. Activation and signaling of the p38MAP kinase pathway. Cell Res 2005;15:11-8.
33. Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002;2:161-74.
34. Stetler-Stevenson WG. Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention. J Clin Invest 1999;103:1237-41.
35. Rundhaug JE. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A. C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res., 9: 00-00, 2003. Clin Cancer Res 2003; 9:551-4.
36. Fang J, Shing Y, Wiederschain D, Yan L, Butterfield C, Jackson G, et al. Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model. Proc Natl Acad Sci U S A 2000;97:3884-9.
37. Li H, Lindenmeyer F, Grenet C, Opolon P, Menashi S, Soria C, et al. AdTIMP-2 inhibits tumor growth, angiogenesis, and metastasis, and prolongs survival in mice. Hum Gene Ther 2001;12:515-26.
38. Gatto C, Rieppi M, Borsotti P, Innocenti S, Ceruti R, Drudis T, et al. BAY 12- 9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity. Clin Cancer Res 1999;5:3603-7.
39. Schnaper HW, Grant DS, Stetler-Stevenson WG, Fridman R, D'Orazi G, Murphy AN, et al. Type IV collagenase(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J Cell Physiol 1993;156:235-46.
40. Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 1998;58:1048-51.
41. Zhou Y, Johnson JL, Cerione RA, Erickson JW. Prenylation and membrane localization of Cdc42 are essential for activation by DOCK7. Biochemistry 2013;52:4354-63.
42. Roberts PJ, Mitin N, Keller PJ, Chenette EJ, Madigan JP, Currin RO, et al. Rho Family GTPase modification and dependence onCAAX motif-signaled posttranslational modification. J Biol Chem 2008;283:25150-63.
43. Guo X,WangM, Jiang J, Xie C, Peng F, Li X, et al. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. Mol Cancer Res 2013;11:230-9.
44. Gastonguay A, Berg T, Hauser AD, Schuld N, Lorimer E, Williams CL. The role of Rac1 in the regulation ofNF-kallppaB activity, cell proliferation, and cell migration in non-small cell lung carcinoma. Cancer Biol Ther 2012; 13:647-56.
45. Dokmanovic M, Hirsch DS, Shen Y, Wu WJ. Rac1 contributes to trastuzumab resistance of breast cancer cells: Rac1 as a potential therapeutic target for the treatment of trastuzumab-resistant breast cancer. Mol Cancer Ther 2009;8:1557-69.
46. Major P. The use of zoledronic acid, a novel, highly potent bisphosphonate, for the treatment of hypercalcemia of malignancy. Oncologist 2002;7: 481-91.
47. Kellinsalmi M, Monkkonen H, Monkkonen J, Leskela HV, Parikka V, Hamalainen M, et al. In vitrocomparison of clodronate, pamidronate and zoledronic acid effects on rat osteoclasts and human stem cell-derived osteoblasts. Basic Clin Pharmacol Toxicol 2005;97:382-91.
48. Cucinotto I, Fiorillo L, Gualtieri S, Arbitrio M, Ciliberto D, Staropoli N, et al. Nanoparticle albumin bound Paclitaxel in the treatment of human cancer: nanodelivery reaches prime-time? J Drug Deliv 2013;2013: 905091.
49. Coleman RL, Brady WE, McMeekin DS, Rose PG, Soper JT, Lentz SS, et al. A phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group study. Gynecol Oncol 2011;122:111-5.
50. Atmaca H, Gorumlu G, Karaca B, Degirmenci M, Tunali D, Cirak Y, et al. Combined gossypol and zoledronic acid treatment results in synergistic induction of cell death and regulates angiogenic molecules in ovarian cancer cells. Eur Cytokine Netw 2009;20:121-30.